Skip to main content

What the FDA labels say about taking them together

Capecitabine and leucovorin

Capecitabine's FDA label of February 5, 2026 names leucovorin in its drug interactions section; the leucovorin labels PlainMeds reads (2) do not name capecitabine. The capecitabine label: “Closely monitor for toxicities when XELODA is coadministered with leucovorin. CYP2C9 substrates:”

Check it at the source: the capecitabine FDA label on DailyMed (effective February 5, 2026, H2-Pharma, LLC); the leucovorin FDA label on DailyMed (effective March 19, 2025, Meitheal Pharmaceuticals Inc.).

What does the capecitabine label say about leucovorin?

Capecitabine label, drug interactions

Closely monitor for toxicities when XELODA is coadministered with leucovorin. ( 7.1 ) CYP2C9 substrates:

Source: FDA drug label (XELODA), NDA020896 (Cheplapharm), as published by H2-Pharma, LLC, effective February 5, 2026 (SPL set e702d84d-7162-4751-bf37-d724cc7e45a5), via openFDA; the full label on DailyMed

What does the leucovorin label say about capecitabine?

Leucovorin's label (effective March 19, 2025) and its 1 other brand-application label do not name capecitabine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (leucovorin calcium), Meitheal Pharmaceuticals Inc., effective March 19, 2025 (SPL set 9df20901-6980-4d4e-89ec-40f3c1f91852), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

18Capecitabine generic labelers
16Leucovorin generic labelers
CapecitabineLeucovorin
Labeled forColorectal cancer, Breast cancerColorectal cancer
Boxed warningYesNo
Pharmacy cost (NADAC)$0.456 per tablet 500 mg tablet$0.330 per tablet 5 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?